Recerca

PreFIT

Predicting the Future: Incipient Tuberculosis

Logo PreFIT
Durada
January 2020 - December 2024
Coordinador
Frank Cobelens (University of Amsterdam)
Finançadors
European and Developing Countries Clinical Trials Partnership (EDCTP)
PreFIT aims to validate assays for improved prediction of progression from latent tuberculosis infection (LTBI) to active tuberculosis (TB) disease. Assays with high positive predictive value (PPV) for progression to TB disease have great potential for reducing TB morbidity and mortality in Africa by allowing scale-up of preventive treatment, which is becoming possible with shorter, safer preventive treatment regimens. PreFIT will achieve high PPV for progression to TB disease with a package of assays that diagnose incipient TB, a stage of LTBI progressing towards disease that can be halted with preventive treatment. These assays test for specific messenger RNA, C-reactive protein and hemoglobin on field-friendly platforms. PreFIT will take the next step in development of these novel and existing assays by validating them prospectively at point-of-care for their clinical performance, feasibility and cost in a cohort of TB-exposed household contacts. These contacts will be followed for 12 months for progression to TB disease, and we will compare test results among participants who do, versus participants who don’t progress to TB disease. In addition, PreFIT will validate iron homeostasis markers retrospectively on the samples collected in the cohort. Robust plans will ensure assay uptake and capacity building.

Our Team

Equip ISGlobal

Altres projectes

Veure projectes passats

CARE

Linkage and retention in care following home-based HIV testing serosurveys in Manhiça District, Southern Mozambique

Xpatial-TB

Improved case detection through TB contact risk stratification by Xpert results and spatial parameters in Mozambique

METRO

Measuring community prevalence among HIV exposed children in rural Southern Mozambique

MAMAH

Improving Maternal and Infant Health by reducing malaria risks in African women: evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women

www.mamahproject.net

VINCI

Optimizing provider-initiated HIV testing, linkage, and retention in care in the district of Manhiça, Mozambique